Esomeprazole magnesium

This page contains recent news articles, when available, and an overview of Esomeprazole magnesium but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

Overview:

Esomeprazole magnesium (when available)

Pharmacology and use:
Omeprazole is a compound that inhibits gastric acid secretion and is indicated in the treatment of gastroesophageal reflux disease (GERD), the healing of erosive esophagitis, and H. pylori eradication to reduce the risk of duodenal ulcer recurrence. Omeprazole belongs to a new class of antisecretory compounds, the substituted benzimidazoles, that do not exhibit anticholinergic or H2 histamine antagonistic properties, but that suppress gastric acid secretion by specific inhibition of the H⁺/K⁺ ATPase enzyme system at the secretory surface of the gastric parietal cell. Because this enzyme system is regarded as the acid (proton) pump within the gastric mucosa, Omeprazole has been characterized as a gastric acid-pump inhibitor, in that it blocks the final step of acid production. This effect is dose-related and leads to inhibition of both basal and stimulated acid secretion irrespective of the stimulus. For the treatment of gastroesophageal reflux disease

Mechanism Of Action:
Omeprazole is a proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the H⁺/K⁺-ATPase in the gastric parietal cell. By acting specifically on the proton pump, Omeprazole blocks the final step in acid production, thus reducing gastric acidity.

News Articles on Omeprazole

POZEN Announces April 30, 2009 Webcast of First Quarter 2009 Results  -  ‎Apr 16, 2009‎
...in adults, and with AstraZeneca for proprietary fixed dose combinations of naproxen with the proton pump inhibitor esomeprazole magnesium in a single MarketWatch (press release)

FDA Safety Changes: Tracleer, Nexium, Nexium IV, Tygacil  -  ‎Apr 1, 2009‎
On January 15, the FDA approved safety labeling revisions for esomeprazole sodium injection (Nexium IV, AstraZeneca) and esomeprazole magnesium Medscape

POZEN to Present at the Cowen and Company 29th Annual Healthcare ...  -  ‎Mar 4, 2009‎
...in adults, and with AstraZeneca for proprietary fixed dose combinations of naproxen with the proton pump inhibitor esomeprazole magnesium in a single MarketWatch (press release)

Genzyme Corp.: Chronic Kidney Disease Patients on Dialysis Must ...  -  ‎Mar 2, 2009‎
...of AstraZeneca's stomach acid drug Nexium (esomeprazole magnesium), which many experts say has the exact same clinical effect as Prilosec (omeprazole). Atlantic Information Services, Inc.

10-K: POZEN INC /NC  -  ‎Mar 6, 2009‎
...to co-develop and commercialize proprietary fixed dose combinations of the PPI esomeprazole magnesium with the NSAID naproxen in a single tablet using MarketWatch (press release)

POZEN Reports Fourth Quarter and Year End 2008 Results  -  ‎Feb 25, 2009‎
...in adults, and with AstraZeneca for proprietary fixed dose combinations of naproxen with the proton pump inhibitor esomeprazole magnesium in a single MarketWatch (press release)

POZEN Informed by FDA That Endoscopic Gastric Ulcer Incidence ...  -  Jan 29, 2009
...in adults, and with AstraZeneca for proprietary fixed dose combinations of naproxen with the proton pump inhibitor esomeprazole magnesium in a single Carolina Newswire (press release),

Ranbaxy Lab swings to loss for FY 08  -  Jan 22, 2009
Ranbaxy reached several agreements with AstraZeneca settling patent infringement litigation for Nexium® (Esomeprazole Magnesium). Myiris.com,

AstraZeneca Submits sNDA for NEXIUM(R) for the Short-Term ...  -  Dec 19, 2008
The formulation contains esomeprazole magnesium, the same active ingredient used in NEXIUM Delayed-Release Capsules. The sNDA submission for NEXIUM in PR Newswire (press release),

POZEN To Participate in The RBC Capital Markets 2008 Healthcare ...  -  Dec 2, 2008
...and with AstraZeneca for proprietary fixed dose combinations of naproxen with the proton pump inhibitor esomeprazole magnesium in a single tablet for Trading Markets (press release),

POZEN Announces Positive Top Line Results for Its PN 400 Phase 3 ...  -  Dec 3, 2008
...and with AstraZeneca for proprietary fixed dose combinations of naproxen with the proton pump inhibitor esomeprazole magnesium in a single tablet for Earthtimes (press release),

AstraZeneca Appoints Rich Fante as President of its US Business  -  Nov 18, 2008
...including Vice President-Primary Care for the gastrointestinal and respiratory franchises, including NEXIUM(R) (esomeprazole magnesium) and PULMICORT SYS-CON Media,

XplosiveStocks.com: AstraZeneca (NYSE: AZN) Hot Stock on the Move!  -  Nov 19, 2008
...the gastrointestinal and respiratory franchises, including NEXIUM (esomeprazole magnesium) and PULMICORT RESPULES (budesonide inhalation suspension). Trading Markets (press release),

POZEN'S PA32520 Study Data Demonstrated Better Upper ...  -  Nov 11, 2008
...and with AstraZeneca for proprietary fixed dose combinations of naproxen with the proton pump inhibitor esomeprazole magnesium in a single tablet for MarketWatch

POZEN Reports Third Quarter 2008 Results  -  Oct 29, 2008
...in adults, and with AstraZeneca for proprietary fixed dose combinations of naproxen with the proton pump inhibitor esomeprazole magnesium in a single MarketWatch

Court Report  -  Oct 19, 2008
...an ANDA to manufacture a generic version of AstraZeneca's Nexium® (esomeprazole magnesium, used for the treatment of gastroesophageal reflux disease). Patent Docs,

POZEN Confirms ANDA Filing for Treximet(R) Tablets  -  Oct 17, 2008
...in adults, and with AstraZeneca for proprietary fixed dose combinations of naproxen with the proton pump inhibitor esomeprazole magnesium in a single MarketWatch

POZEN To Present at The UBS Life Sciences Conference  -  Sep 10, 2008
...and with AstraZeneca for proprietary fixed dose combinations of naproxen with the proton pump inhibitor esomeprazole magnesium in a single tablet for MarketWatch

POZEN To Present at the 3rd Annual Citi Biotech Day  -  Aug 26, 2008
...and with AstraZeneca for proprietary fixed dose combinations of naproxen with the proton pump inhibitor esomeprazole magnesium in a single tablet for Business Wire (press release),

Romancing the Enemy Pays Off for Drug Companies  -  Aug 5, 2008
Ranbaxy will also manufacture Nexium’s active ingredient esomeprazole magnesium for AstraZeneca from May 2009. Beginning May 2010, Ranbaxy will also NJBIZ,

POZEN to Present at the 2008 BMO Capital Markets Focus on ...  -  Jul 24, 2008
...and with AstraZeneca for proprietary fixed dose combinations of naproxen with the proton pump inhibitor esomeprazole magnesium in a single tablet for MarketWatch

POZEN Receives Initial FDA Response To PA32540 SPA  -  Aug 2, 2008
...in adults, and with AstraZeneca for proprietary fixed dose combinations of naproxen with the proton pump inhibitor esomeprazole magnesium in a single FOXBusiness

POZEN Announces July 29, 2008 Webcast of Second Quarter 2008 Results  -  Jul 15, 2008
...and with AstraZeneca for proprietary fixed dose combinations of naproxen with the proton pump inhibitor esomeprazole magnesium in a single tablet for WELT ONLINE,

POZEN Reports Second Quarter 2008 Results  -  Jul 29, 2008
...in adults, and with AstraZeneca for proprietary fixed dose combinations of naproxen with the proton pump inhibitor esomeprazole magnesium in a single Business Wire (press release),

A Journey to Continence: A Case Study of Overactive Bladder Syndrome  -  Jul 23, 2008
Her prescribed medications included amlodipine besylate (Norvasc(R)) 10 mg, esomeprazole magnesium (Nexium(R)) 40 mg, venlafaxine hydrochloride (Effexor RedOrbit,

Dr Reddy's follows Teva on Nexium  -  Jun 5, 2008
...and Ranbaxy have also entered into a manufacturing contract for supply raw material for making esomeprazole magnesium to AstraZeneca from 2009 onwards. Sify,

Now, Ranbaxy seeks peace with Takeda  -  Jun 21, 2008
During the 180-day period following the date, Ranbaxy will distribute the only generic Esomeprazole magnesium product in the US market. Business Standard,

POZEN To Present at the Jefferies 2 nd Annual Healthcare Conference  -  Jun 16, 2008
...and with AstraZeneca for proprietary fixed dose combinations of naproxen with the proton pump inhibitor esomeprazole magnesium in a single tablet for Business Wire (press release),

AstraZeneca Submits sNDA for Nexium IV  -  Jun 6, 2008
...for 30 minutes plus an IV infusion of Nexium 8 mg per hour for 72 hours, followed by oral Nexium (esomeprazole magnesium) 40 mg once daily for 27 days. FDA news (subscription),

Indian drugs maker Ranbaxy taken over by Japan's Daiichi Sankyo  -  Jun 11, 2008
The Indian group will manufacture supplies of the active ingredient in the drug, esomeprazole magnesium, from May 2009. Times Online,

POZEN Demonstrates Bioequivalence To Enteric Coated Aspirin For ...  -  Jun 11, 2008
...and with AstraZeneca for proprietary fixed dose combinations of naproxen with the proton pump inhibitor esomeprazole magnesium in a single tablet for Medical News Today (press release),

ESOMEPRAZOLE SODIUM - Drug information  -  02 Jun 2008
...as an alternative to oral therapy in patients when therapy with Nexium (esomeprazole magnesium) Delayed-Release Capsules is not possible or appropriate. Lifescience-online,

POZEN To Present at the Seventh Annual Needham & Co., LLC ...  -  02 Jun 2008
...and with AstraZeneca for proprietary fixed dose combinations of naproxen with the proton pump inhibitor esomeprazole magnesium in a single tablet for Ad-Hoc-News (Pressemitteilung),

POZEN To Present at the Seventh Annual Needham & Co., LLC ...  -  02 Jun 2008
...and with AstraZeneca for proprietary fixed dose combinations of naproxen with the proton pump inhibitor esomeprazole magnesium in a single tablet for Business Wire (press release),

Settling it out  -  May 13, 2008
Two of these agreements concern esomeprazole magnesium capsules (the active ingredient in Nexium), while the third pertains to omeprazole 40mg tablets, Express Pharma,

AstraZeneca Submits sNDA for NEXIUM(R) IV for Peptic Ulcer Bleed ...  -  May 30, 2008
...an alternative to oral therapy in patients when therapy with NEXIUM(R) (esomeprazole magnesium) Delayed-Release Capsules is not possible or appropriate. Earthtimes (press release),

Healthy partnerships  -  May 11, 2008
The deal with Astra Zeneca on Esomeprazole magnesium, the generic equivalent of Nexium, the second largest selling drug in the US with sales of $5.5 billion Business Standard,

Pozen Announces PN 200 Podium Presentation at Digestive Disease Week  -  May 19, 2008
...and with AstraZeneca for proprietary fixed dose combinations of naproxen with the proton pump inhibitor esomeprazole magnesium in a single tablet for PharmaLive.com (press release),

POZEN Announces PN 200 Podium Presentation At Digestive Disease Week  -  May 21, 2008
...and with AstraZeneca for proprietary fixed dose combinations of naproxen with the proton pump inhibitor esomeprazole magnesium in a single tablet for Medical News Today (press release),

AstraZeneca, Ranbaxy Ink Manufacturing Agreements  -  May 29, 2008
Under the agreements, generic drugmaker Ranbaxy will formulate a portion of AstraZeneca's US supply of Nexium (esomeprazole magnesium) starting in May 2010. Pharmaceutical Online (press release),

POZEN To Present at the Citigroup Global Healthcare Conference  -  May 15, 2008
...and with AstraZeneca for proprietary fixed dose combinations of naproxen with the proton pump inhibitor esomeprazole magnesium in a single tablet for PR-Inside.com (Pressemitteilung),

McKesson Sued for Alleged Drug Price Manipulation  -  May 22, 2008
...heartburn drug Nexium (esomeprazole magnesium) and diazepam, sold by Roche under the brand name Valium, as examples of allegedly overpriced drugs. FDA news (subscription),

Streetinvesting.com: POZEN To Present at the Citigroup Global ...  -  May 15, 2008
...and with AstraZeneca for proprietary fixed dose combinations of naproxen with the proton pump inhibitor esomeprazole magnesium in a single tablet for Trading Markets (press release),

POZEN IND and NDA for Treximet™ (Sumatriptan/Naproxen Sodium ...  -  May 14, 2008
...and with AstraZeneca for proprietary fixed dose combinations of naproxen with the proton pump inhibitor esomeprazole magnesium in a single tablet for Business Wire (press release),

NPS Appoints Dr. Bo Joelsson as Head of Clinical Research  -  May 13, 2008
...development of several major gastrointestinal products, including Tagamet® (cimetidine), Prilosec® (omeprazole), and Nexium® (esomeprazole magnesium). Business Wire (press release),

Brand Names/Synonyms:
Esomeprazole magnesium is also known by the following brand names and/or synonymsAntra; Antra Mups; Audazol; Aulcer; Belmazol; CCRIS 7099; Ceprandal; Danlox; Demeprazol; Desec; Dizprazol; Dudencer; Elgam; Emeproton; Epirazole; Erbolin; Esomeprazole; Esomeprazole Magnesium; Exter; Gasec; Gastrimut; Gastroloc; Gibancer; H 168/68; HSDB 3575; Indurgan; Inhibitron; Inhipump; Lensor; Logastric; Lomac; Losec; Mepral; Miol; Miracid; Mopral; Morecon; Nexium; Nexium Iv; Nilsec; Nopramin; OMEP; OMEPRAZOLE; OMP; OMZ; Ocid; Olexin; Omapren; Omebeta 20; Omed; Omegast; Omepral; Omeprazol [Inn-Spanish]; Omeprazole; Omeprazole [Usan:Ban:Inn:Jan]; Omeprazolum [Inn-Latin]; Omeprazon; Omeprol; Omesek; Omezol; Omezolan; Omid; Omisec; Omizac; Ompanyt; Ortanol; Osiren; Ozoken; Paprazol; Parizac; Pepticum; Pepticus; Peptilcer; Prazentol; Prazidec; Prazolit; Prilosec; Prilosec Otc; Procelac; Proclor; Prysma; Ramezol; Regulacid; Result; Sanamidol; Secrepina; Tedec Ulceral; Ulceral; Ulcesep; Ulcometion; Ulcozol; Ulcsep; Ulsen; Ultop; Ulzol; Victrix; Zefxon; Zegerid; Zepral; Zimor; Zoltum

Drug Category:
Esomeprazole magnesium is categorized under the following by the FDA: Anti-ulcer Agents; Proton-pump Inhibitors; ATC:A02BC01; ATC:A02BC05

Dosage Forms:
Oral tablets

Absorption:
Absorption is rapid, Absolute bioavailability (compared to intravenous administration) is about 30-40% at doses of 20-40 mg

Interactions:
-->Interactions for Omeprazole:

Other

Omeprazole can prolong the elimination of diazepam, warfarin and phenytoin, drugs that are metabolized by oxidation in the liver. Although in normal subjects no interaction with theophylline or propranolol was found, there have been clinical reports of interaction with other drugs metabolized via the cytochrome P-450 system (e.g., cyclosporine, disulfiram, benzodiazepines). Patients should be monitored to determine if it is necessary to adjust the dosage of these drugs when taken concomitantly with omeprazole.

Because of its profound and long lasting inhibition of gastric acid secretion, it is theoretically possible that omeprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (e.g., ketoconazole, ampicillin esters, and iron salts). In the clinical trials, antacids were used concomitantly with the administration of omeprazole.

Combination Therapy with Clarithromycin

Co-administration of omeprazole and clarithromycin may result in increases in plasma levels of ompeprazole, clarithromycin, and 14-hydroxy-clarithromycin.

Concomitant administration of clarithromycin with cisapride, pimozide, or terfenadine is contraindicated.

There have been reports of an intereaction between erythromycin and astemizole resulting in QT prolongation and torsades de points. Concomitant administration of erythromycin and astemizole is contraindicated. Because clarithromycin is also metabolized by cytochrome P450, concomitant administration of clarithromycin with astemizole is not recommended.

Chemical IUPAC Name:
5-methoxy-2-[(4-methoxy-3,5-dimethyl-pyridin-2-yl)methylsulfinyl]-3H-benzoimidazole

:

Web health.mongabay.com/health

Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on health.mongabay.com/health lead to other sites. health.mongabay.com/health does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is health.mongabay.com/health responsible for dead or misdirected links.